The main report of "Building China's Pharmaceutical Innovation Ecosystem (2021-2025)" was officially released to help build China's pharmaceutical innovation powerhouse

"Building China's Pharmaceutical Innovation Ecosystem (2021-2025)" report conference was held in Beijing.
The report was organized by China Pharmaceutical Innovation Promotion Association (China Pharmaceutical Promotion Association) and China Association of Foreign Investment Enterprises Drug Research and Development Industry Committee (RDPAC) Co-organize and write
.
At the press conference, Feng Lan, Secretary General of China Pharmaceutical Promotion Association, shared the main research results of the report; Song Ruilin, Executive Chairman of China Pharmaceutical Promotion Association, and Kang Wei, Executive President of RDPAC, shared their contribution to the construction of China's pharmaceutical innovation ecosystem from domestic and international perspectives.

During the "Thirteenth Five-Year Plan" period, the construction of China's pharmaceutical innovation ecosystem has undergone a major historical turning point.
China's pharmaceutical innovation has injected new vitality, and the innovation ecosystem has been initially established with remarkable results
.
The “Fourteenth Five-Year Plan for National Economic and Social Development of the People’s Republic of China and the Outline of Long-term Goals for 2035” released this year further emphasizes the core position of innovation in modern development, and clearly proposes to strengthen scientific and technological frontier research in the field of biomedicine.

In response to the requirements of the times, the China Pharmaceutical Promotion Association and RDPAC started in early 2021 and organized and wrote 4 reports, focusing on "2015-2020 development review and future prospects", "promoting basic research, activating the source of innovation", and "multi-level medical care".
We will conduct detailed and in-depth analysis in the professional fields of “Guarantee System, Helping People’s Health and High-quality Industrial Development” and “Promoting the Synchronous R&D, Registration and Evaluation of Innovative Drugs”, aiming to follow “innovative industry competitiveness” and “innovative drug accessibility”.
The three main lines of "Sustainable Innovative Pharmaceutical Industry" and "Innovative Pharmaceutical Industry" put forward multi-dimensional constructive opinions on the long-term development of China's innovative pharmaceutical ecosystem, and empowered the high-quality development of China's pharmaceutical innovation
.
Since its inception, the project has received careful guidance from the advisory committee, and received support from more than 30 experts from politics, industry, academia, research, and capital

According to the press conference, in the past five years, China has built a vital pharmaceutical innovation industry with the advanced concepts of the innovation ecosystem, the top-level design vigorously promoted from top to bottom, and the fair competition and highly integrated innovative enterprises
.
However, what weaknesses and challenges still exist in the entire industry chain at this stage? How can my country's medical innovation truly realize original innovation? How can the efficiency and quality of R&D be internationalized? What kind of innovative drug payment system will be constructed to improve the level of protection? Where is the future innovative development of Chinese medicine? The report gives directions and suggestions on these key issues, and it is expected that China's pharmaceutical innovation will be practiced and explored in the development of the next five years

Activate the source of innovation, and build a system and ability to transform basic research into industry
.
At present, the quality and quantity of China's pharmaceutical innovation are advancing, and the number of R&D pipeline products accounted for 13.

Realize simultaneous research and development, improve the scientific nature of registration supervision and the efficiency of clinical research
.
Previously, new drugs were approved in China 5-7 years later than in the United States on average.

To meet the needs of accessibility, we will construct a multi-level payment guarantee network
.
The analysis of the report pointed out that in the future, in China, improving the prevention and treatment of the three major diseases of cancer, chronic diseases, and infectious diseases will effectively improve the health of the whole people

Guide innovative thinking and focus on the core orientation of clinical value
.
The report emphasizes that clinical value is the core of drug R&D evaluation.

China's pharmaceutical industry is facing a great opportunity to move towards high-quality development by leaps and bounds.
The development direction and planning in the next five years are crucial to building China's pharmaceutical innovation power.
The goal of building China's pharmaceutical innovation ecosystem will center on the frontiers of science and technology, innovation systems, and innovative industries.
, Four aspects of people's health, to achieve a leapfrog breakthrough in the overall goal
.

Song Ruilin, Executive Chairman of China Pharmaceutical Innovation Promotion Association

Song Ruilin, executive chairman of the China Pharmaceutical Promotion Association, said: "At present, a new round of scientific and technological revolution and industrial transformation are in-depth development.
After the baptism of the global epidemic and prevention and control of the new crown epidemic, the level of medical innovation plays an even more important role in controlling the epidemic and restoring the economy.
Highlighted
.
China is at an important historical node in moving from a major pharmaceutical manufacturing country to a powerful pharmaceutical innovation country.
It needs to climb high and look far and take advantage of the
trend.
We hope that through this report, we can achieve a higher-quality development of China's pharmaceutical innovation and take the posture of a strong pharmaceutical innovation country.
Promote the establishment of a human health community
.
"

Conway, Executive President, Pharmaceutical Research and Development Industry Committee (RDPAC), China Association of Enterprises with Foreign Investment

Conway, CEO of RDPAC, said: “The series of research reports on "Building China's Pharmaceutical Innovation Ecosystem" lasted for nearly a year and gathered support and contributions from multiple sources at home and abroad.
Long-term development empowerment
.
At present, China's pharmaceutical innovation ecosystem is initially formed, and breakthroughs in original innovation still require long-term accumulation and development.
In the future, we look forward to establishing a multi-level medical security system that the government and the market economy share, and promote China's entry into the world.
Mutual recognition of early clinical layout and international clinical trial data will ultimately enable patients to use innovative and good medicines as soon as possible.

RDPAC and member companies also look forward to continuing to share and provide world-leading medical innovation experience, so as to inject a steady stream of medical innovation in China Motivation to bring well-being to Chinese patients
.
"

About China Pharmaceutical Innovation Promotion Association

The China Association for the Promotion of Pharmaceutical Innovation (hereinafter referred to as the China Association for the Promotion of Pharmaceuticals) was established in 1988 and is a non-profit national 4A social organization registered with the Ministry of Civil Affairs
.
Adhering to the tenet of “innovation, industrialization, and internationalization”, the China Association for the Promotion of Pharmaceuticals has long been committed to the close integration of “production, education, research and funding” to promote the innovation and development of the pharmaceutical industry.
It has become an enterprise integrating pharmaceutical innovation and R&D The pharmaceutical innovation industrialization promotion platform composed of scientific research institutions, clinical research institutions, innovation service institutions and pharmaceutical investment institutions currently has 157 member units
.
China Pharmaceutical Promotion Association has established drug research and development, drug clinical trial research, medical policy, medical innovation investment, innovative research and development services, cardiovascular drug clinical research, international innovative drug supervision, anti-tumor drug clinical research, neurological drug clinical research, medicine Corporate Compliance, Diabetes and Metabolic Disease Drug Clinical Research Professional Committee has formed a full-chain organizational structure covering drug R&D, production, use, investment and financing with innovation as the core and promoting innovation as the goal, and serves as an international drug manufacturer The members of the Federation of Associations (IFPMA) continue to expand international communication channels
.

About the Pharmaceutical Research and Development Industry Committee of the China Association of Enterprises with Foreign Investment

The Pharmaceutical Research and Development Industry Committee of the China Association of Enterprises with Foreign Investment (RDPAC) is a non-profit organization composed of 45 multinational pharmaceutical companies with research and development capabilities.
It was established in 1999 and belongs to the "China Association of Enterprises with Foreign Investment
.
" As of June 2020, RDPAC member companies have established 47 factories and 25 R&D centers in Mainland China
.
RDPAC members share the same aspiration with the Chinese government and local pharmaceutical companies, that is, hope that China will become a major country in pharmaceutical innovation
.
RDPAC looks forward to having the opportunity to work together and develop collaboratively with the Chinese government to realize this wish and enable innovative drugs to benefit more Chinese and global patients
.

Construction of China's pharmaceutical innovation ecosystem (2021-2025)